
|Videos|June 4, 2021
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals drop in development for treating presbyopia
Advertisement
Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Takeaways from this week in optometry: August 10-August 14
2
WaveDȳn integrates with Bausch + Lomb and WAVE for scleral lens fitting
3
Study finds that current ophthalmic patient letters may pose comprehension difficulty
4














